A rare case of severe myopathy associated with etravirine use

AIDS

Volumn 24, Issue 7, 2010, Pages 1088-1090

  Tommasi, Chiara ^a   Tempestilli, Massimo ^a   Fezza, Rita ^a   Bellagamba, Rita ^a   Nicastri, Emanuele ^a   D'Offizi, Gianpiero ^a   Pucillo, Leopoldo P ^a   Narciso, Pasquale ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BISOPROLOL; DARUNAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; RALTEGRAVIR;

ADULT; ANAMNESIS; CASE REPORT; CLINICAL FEATURE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; MYOPATHY; PRIORITY JOURNAL; RHABDOMYOLYSIS;

ANTI-HIV AGENTS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUSCULAR DISEASES; PYRIDAZINES;

EID: 77950919421     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283382f65     Document Type: Letter

References (9)

1. Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48:4680-4686.
2. Madruga JV, Cahn P,Grinsztejn B, Haubrich R, Lalezari J, Mills A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:29-38.
3. Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:39-48.
4. Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Molina JM, et al. Efficacy and safety of etravirine in treatment experienced, HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009; 23:2289-2300.
5. Evering TH, Markowitz M. Raltegravir: an integrase inhibitor for HIV-1. Expert Opin Investig Drugs 2008; 17:413-422.
6. Isentress [package insert]. Whiteshouse Station New Jersey: Merck & Co. Inc.; 2007.
7. Connelly S. Raltegravir NDA 22-145. U.S. Food and Drug Administration Division of Antiviral Products Antiviral Drugs Advisory Committee Meeting; 5 September 2007: http://www.fda.gov/OHRMS/DOCKETS/AC/07/slides/2007-4314s1-06 connelly.ppt#256,1,Raltegravir NDA 22-145.
8. FDA approves new HIV drug. Raltegravir tablets used in combination with other antiretroviral agents. FDA News; 16 October 2007. http://www.fda.gov/bbs/ topics/NEWS/2007/NEW01726. html.
9. Zembower TR, Gerzenshtein L, Coleman K, Palella FJ Jr. Severe rhabdomyolysis associated with raltegravir use. AIDS 2008; 22:1382-1384.